The manufacturer's device analysis results: for this issue to occur: the abnormal termination has to occur during the intersegment after mlc/bm control system loads the next shape and before the linac control system loads its next segment which clears the dose.I.E.The condition which contributes to the hazard is that the incremented control point still has dose associated with it.The dose display will show the actual dose delivered.A finish field is created which uses the incorrect control point for the dose delivered, resulting in a finish field which will underdose.The user delivers the finish field, underdosing the patient without realising that there is anything wrong.Mosaiq records that the total prescribed dose was delivered: the linac dose counter will show the actual dose delivered for the finish field.The following warning is in the integrity 3.1 instructions for use - clinical mode manual, which if followed, would detect this issue: warning 5.2; when an abnormal termination of a field occurs, you must look at the beam mu display and record the value.You must do a check, in the r&v system, that the remaining mu to be delivered in the finish field that results is correct before you continue.If you ignore this warning, it can cause clinical mistreatment.This issue has been fixed in integrity 3.2; during delivery, if the accumulated segment dose for a beam is more than a set value mu greater than the beam dose, the system shall terminate the beam and set the accumulated segment dose to the beam dose.Remedial action/corrective action/preventive action / field safety corrective action this issue has been resolved in integrity 3.2 which has been released as a mandatory modification kit to the field.Time schedule for the implementation of the identified actions: this modification kit has already been released.Further investigations: none.Is the manufacturer aware of similar incidents with this type of medical device with a similar root cause? yes - 2 (b)(6).The following has been updated: email address updated.The following has been updated: establishment name.The following has been updated: manufacturing site/address has been updated.Resubmitting form 3500a due to an administrative error.This has now been corrected so that only "initial" has been checked and not both "initial" and "follow-up" as requested by fda medwatch program department.Correction ticked.The method code and result code that were used in the previous report submitted on 03/31/2015 are obsolete.(b)(4).
|